The short answer: Primary peritoneal carcinoma (PPC) is a rare cancer closely related to ovarian cancer that arises from the lining of the abdominal cavity. End-of-life care for advanced PPC mirrors advanced ovarian cancer management, focusing on abdominal symptom control, ascites management, bowel function, and quality of life.

What to Expect With Primary Peritoneal Carcinoma End-of-Life Care

Primary peritoneal carcinoma is biologically and clinically nearly identical to high-grade serous ovarian cancer — so similar that the same treatment protocols are used and outcomes are comparable. This guide will help families understand what to expect when PPC is advanced and treatment options are exhausted.

Understanding Primary Peritoneal Carcinoma

PPC arises from the peritoneum — the lining of the abdominal cavity — rather than the ovaries themselves. It presents and behaves like Stage III-IV ovarian cancer: abdominal distension, CA-125 elevation, and widespread peritoneal spread. It is often found incidentally (in women who have had their ovaries removed) or presents with late symptoms of advanced disease.

Treatment Trajectory

Treatment follows ovarian cancer protocols: platinum-based chemotherapy (carboplatin/paclitaxel), often with bevacizumab, and PARP inhibitors for BRCA-mutated cases. Most patients initially respond but eventually develop platinum-resistant disease. Once platinum-resistant PPC stops responding to multiple lines of therapy, the transition to palliative and end-of-life care is appropriate.

Key End-of-Life Symptoms

Ascites: The most challenging symptom — fluid accumulation in the abdomen causing distension, discomfort, and breathing difficulty. Palliative paracentesis (draining the fluid) provides temporary relief; an indwelling peritoneal catheter (PleurX drain) allows home drainage and reduces hospital visits.

Bowel obstruction: Peritoneal disease can impair bowel motility causing obstruction. Management ranges from dietary modification to venting gastrostomy to octreotide for secretion reduction.

Pain: Abdominal and pelvic pain managed with opioids, nerve blocks, and palliative radiation to specific tumor masses.

Fatigue and malnutrition: Progressive as disease advances; nutrition support is palliative in focus.

BRCA Status and Family Implications

PPC is associated with BRCA1/2 mutations. If the patient hasn't had genetic testing, end-of-life may be an important time to complete hereditary testing and share results with daughters and sisters who may benefit from risk-reducing surgery. Genetic counselors can navigate this sensitively.

Hospice and Home Care

PPC patients benefit from early hospice enrollment. Home paracentesis via PleurX drain, home infusion nursing, and palliative care team coordination can allow comfortable death at home if that is the patient's wish.

Frequently Asked Questions

What is primary peritoneal carcinoma?

Primary peritoneal carcinoma (PPC) is a rare cancer that arises from the peritoneum — the thin tissue lining the abdominal cavity — rather than the ovaries. It is biologically nearly identical to high-grade serous ovarian cancer, treated with the same chemotherapy protocols, and has similar outcomes. It can occur even in women whose ovaries have been surgically removed.

What are symptoms of advanced primary peritoneal carcinoma?

Advanced PPC symptoms include abdominal distension from ascites (fluid accumulation), abdominal and pelvic pain, early satiety and nausea, bowel obstruction causing vomiting, profound fatigue, significant weight loss and malnutrition, shortness of breath if ascites is pushing on the diaphragm, and progressive decline in function.

What is a PleurX drain and how does it help?

A PleurX drain (indwelling peritoneal catheter) is a small tube placed through the abdominal wall that allows patients and caregivers to drain ascites fluid at home, typically 2-3 times per week. It eliminates the need for repeated hospital or clinic visits for paracentesis (fluid drainage) and significantly improves comfort and quality of life in end-stage PPC.

Is primary peritoneal carcinoma hereditary?

Yes, PPC is associated with BRCA1 and BRCA2 gene mutations at similar rates to high-grade serous ovarian cancer (about 15-20% of cases). If the patient hasn't been tested, genetic testing during or after diagnosis is important — first-degree female relatives (daughters, sisters) may benefit from genetic counseling and risk-reducing surgery if a BRCA mutation is identified.

When should hospice be considered for primary peritoneal carcinoma?

Hospice is appropriate for PPC when platinum-resistant disease has stopped responding to available treatment options, when the burden of treatment outweighs potential benefit, when performance status has significantly declined, or when the patient's goals prioritize comfort and quality of remaining life. Early enrollment allows better symptom management, especially for ascites.

Renidy connects grieving families with compassionate death doulas and AI-powered funeral planning tools. Try our free AI funeral planner or find a death doula near you.